18F-FDG PET/CT影像组学预测胰腺导管腺癌总生存期:两中心研究
本研究纳入109例胰腺导管腺癌患者,利用术前18F-FDG PET/CT影像组学特征和临床因素建立多个模型预测总生存期。中位随访28个月,68例(62.4%)死亡,中位OS为15个月。测试集中整合模型C-index最高为0.743,PET-based模型显著优于临床模型(P=0.027),但进一步特征整合未提升性能。
要点
- 基于PET的影像组学模型预测PDAC总生存期显著优于临床模型(P=0.027)。
- CT-based模型与临床模型差异未达统计学显著(P=0.057)。
- 整合模型测试集C-index为0.743,但较PET/CT-based模型未见提升。
核心结论
- 18F-FDG PET/CT影像组学特征在预测PDAC患者总生存期方面显示出潜力,可能作为个体化管理的工具,但需大规模研究确认其临床适用性。
研究设计与样本
- 两中心回顾性研究,纳入109例胰腺导管腺癌患者(70例男性,39例女性),利用术前18F-FDG PET/CT影像组学特征和临床因素建立预测总生存期的模型。
主要发现
- 中位随访28个月(范围1-64个月),68例(62.4%)死亡,中位OS为15个月。
- 测试集中临床模型、CT-based模型、PET-based模型、PET/CT-based模型和整合模型的C-index分别为0.586、0.724、0.730、0.730和0.743。
- PET-based模型显著优于临床模型(P=0.027),CT-based模型与临床模型差异无统计学意义(P=0.057),进一步特征整合未提升性能。
关键数值与推荐
- 测试集C-index:临床模型0.586,CT-based模型0.724,PET-based模型0.730,PET/CT-based模型0.730,整合模型0.743。
- PET-based模型对比临床模型P=0.027;CT-based模型对比临床模型P=0.057。
临床怎么用
- 术前18F-FDG PET/CT影像组学模型可用于PDAC患者总生存期的无创性预测,辅助个体化治疗决策。
局限性
- 需大规模研究确认影像组学模型在临床实践中的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate prognostic prediction in pancreatic cancer is of paramount clinical importance for patient management. However, a reliable and non-invasive method for preoperatively predicting overall survival (OS) remains a significant unmet need. We aim to evaluate the utility of pre-operative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/ computed tomography (CT)-derived signatures in predicting OS in patients with pancreatic ductal adenocarcinoma (PDAC). RESULTS: This study included 109 patients (70 males, 39 females). Over a median follow-up period of 28 months (range, 1-64 months), 68 patients (62.4%) died (median OS, 15 months). As stated above, a series of models was established using selected radiomics features and clinical factors. In the test set, the C-index of the clinical, CT-based, PET-based, PET/CT-based, and integrated model were 0.586, 0.724, 0.730, 0.730, and 0.743, respectively. The PET-based model (P = 0.027) significantly outperformed the clinical model, unlike the CT-based model (P = 0.057); further feature integration did not improve performance. CONCLUSION: In this study, 18F-FDG PET/CT radiomics features showed promise in predicting OS in patients with PDAC, suggesting potential as a tool for personalized management and warranting large-scale studies to confirm its applicability in clinical practice.
引用
- Xu Y, Shi Y, Jiang T, et al. Predicting overall survival in pancreatic ductal adenocarcinoma using 18F-FDG PET/CT radiomics: a two-center study. EJNMMI Res. 2026. PMID: 41733855. doi:10.1186/s13550-026-01399-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。